Osel Announces Positive Results from Phase 1b Trial of Live Biotherapeutic Product CBM588 in Combination with Checkpoint Inhibitor (CPI) Therapy in Metastatic Renal Cell Carcinoma

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Osel announces positive results presented at ASCO for Phase 1b trial of live biotherapeutic product CBM588 combined with checkpoint inhibitor therapy.

Click to view original post